- Home
- NUVB
NUVB
Nuvation Bio Inc.
as 07-26-2024 4:00pm EST
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 744.5M | IPO Year: | N/A |
| Target Price: | $6.60 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.95 - $4.16 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Nuvation Bio Inc. News
NUVB Breaking Stock News: Dive into NUVB Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib
Simply Wall St.
14 days ago
We Think Nuvation Bio (NYSE:NUVB) Can Easily Afford To Drive Business Growth
MT Newswires
a month ago
Nuvation Bio Insider Bought Shares Worth $500,089, According to a Recent SEC Filing
The Telegraph
2 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Motley Fool
2 months ago
4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
AFP
2 months ago
Seoul resumes loudspeaker propaganda against North
Simply Wall St.
2 months ago
Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss
Simply Wall St.
2 months ago
American Software Full Year 2024 Earnings: EPS Beats Expectations
Compare NUVB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NUVB Nuvation Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.